Cigna Earnings Call Highlights Growth, EPS Upgrade
📈 Cigna reported Q1 2026 revenue of $68.5 billion with adjusted EPS of $7.79, marking a 16% year-over-year increase.
🚀 Management raised the full-year 2026 adjusted EPS guidance to at least $30.35 despite known headwinds in certain segments.
💊 Evernorth segment revenue grew 9% to $58.4 billion, driven by continued uptake of its health services platform.
🦠 Specialty and Care Services delivered a strong 20% year-over-year pretax adjusted earnings growth to $1.1 billion.
🏥 Cigna Healthcare posted an 18% increase in pretax adjusted earnings with a medical care ratio of 79.8%.
💻 The company reduced prior authorization friction by removing hundreds of tests and procedures, cutting volume by roughly 15%.
🏆 Cigna Healthcare ranked first in J.D. Power's digital experience satisfaction for commercial members for the second consecutive year.
💊 New "Signature" rebate-free pharmacy model offers brand drugs at prices approximately 30% lower with greater transparency.
🤖 An AI predictive high-cost claimant model is generating around $2,000 in annual savings per engaged member.
📉 Pharmacy Benefit Services earnings declined 28% year-over-year due to large client renewals and investments in the new Signature model.
💸 Special items charges of $322 million ($1.22 per share) were recorded but excluded from adjusted metrics as part of transformation efforts.
🔄 Cigna plans to exit the individual exchange business at year-end and is reviewing its eviCore operations.
💰 The company generated $1.1 billion in operating cash flow with a debt-to-capitalization ratio improving to 42.3%.
🤝 Noncontrolling interests climbed to $226 million due to a new joint venture that passes back additional economics to clients.
- Cigna reported Q1 2026 revenue of $68.5 billion with adjusted EPS of $7.79, representing 16% year-over-year earnings growth.
- The company raised its full-year 2026 adjusted EPS guidance to at least $30.35, signaling confidence in sustained demand despite known headwinds.
- Evernorth revenues climbed 9% year-over-year to $58.4 billion, driven by continued uptake of its health services platform.
- Evernorth pretax adjusted earnings reached $1.5 billion, slightly ahead of expectations as it invests heavily in new models and client relationships.
- Specialty and Care Services delivered 20% year-over-year pretax adjusted earnings growth to $1.1 billion, highlighting the importance of higher-margin clinical offerings.
- Cigna Healthcare generated pretax adjusted earnings of $1.5 billion with an 18% increase versus last year, reflecting disciplined underwriting and cost management.
- The medical care ratio improved to 79.8%, which is better than expectations and provides cushion against expected seasonal normalization later in the year.
- Management highlighted a notable reduction in administrative friction, cutting medical prior authorization volume by roughly 15% by removing hundreds of tests from prior authorization in the U.S.
- Cigna Healthcare ranked first in J.D. Power's digital experience satisfaction for commercial members for a second straight year, showcasing strong digital strengths.
- The new 'Signature' rebate-free pharmacy service model offers brand drugs at prices about 30% lower with greater transparency, and early feedback from the selling season has been encouraging.
- A predictive high-cost claimant model is generating around $2,000 in annual savings per engaged member through data and AI initiatives.
- Digital and AI-enabled tools are translating into tangible operating efficiencies, including a 20% reduction in inbound calls for U.S. employer customers among digitally eligible members.
- Pharmacy Benefit Services members drove a 25% decline in inbound calls over the same period, supporting lower service costs and better scalability.
- The company generated $1.1 billion of operating cash flow in Q1 and ended the quarter with a debt-to-capitalization ratio of 42.3%, a 70-basis-point improvement from year-end 2025.
- Cigna recorded after-tax special items charges of $322 million in Q1 2026, which weighed on reported earnings despite being excluded from adjusted metrics.
- Pharmacy Benefit Services pretax adjusted earnings fell 28% year-over-year to $394 million due to large client renewals and upfront investments for the new Signature model.
- The company plans to exit the individual exchange business at year-end, which may trim near-term revenue as part of strategic pruning.
- Management initiated a strategic review of its eviCore operation, creating uncertainty around this segment's future performance and scope.
- Noncontrolling interest climbed to $226 million in the quarter, more than doubling from the prior year due to a new joint venture with a major client.
- The rising noncontrolling interest adds modeling complexity and affects the split of earnings reported to shareholders.
